About
AptaTeck Bio has developed a proprietary technology based on an amplification probe for developing highly sensitive immuno-assays employing both antibodies and aptamers. AptaTeck's signal amplification technology is designed to generate specific, highly sensitive, accurate, and reproducible immune diagnostics assays. It is compatible with a variety of platforms, automated and manual, and could be integrated easily into most current commercial platforms. The system is demonstrated in ELISA assays and flow cytometry. The AptaTeck system is cost effective and enables accurate diagnosis at the point of care. AptaTeck's technology is suitable for the detection of a variety of target molecules including biomarkers, viral and bacterial antigens, nucleic acids, cell surface, and soluble antigens.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary technology developed by AptaTeck Bio?
- AptaTeck Bio has developed a proprietary technology based on an amplification probe for highly sensitive immuno-assays, utilizing both antibodies and aptamers.
- What is the operational status of AptaTeck Bio?
- AptaTeck Bio is currently inactive, having ceased operations in January 2015.
- Where is AptaTeck Bio headquartered?
- AptaTeck Bio is headquartered in Jerusalem, Israel.
- What types of assays has AptaTeck Bio's system been demonstrated in?
- AptaTeck Bio's system has been demonstrated in ELISA assays and flow cytometry.
- What is the primary sector of AptaTeck Bio?
- AptaTeck Bio's primary sector is Health Tech & Life Sciences.
- Who is a founder of AptaTeck Bio?
- Ofer Nussbaum, PhD. is a founder of AptaTeck Bio.
- What is the employee count for AptaTeck Bio?
- AptaTeck Bio has 6 employees.
- What is AptaTeck Bio's current funding stage?
- AptaTeck Bio is in the Pre-Funding stage.